Laser bioprinting device and in vivo applicationsbroad
Laser bioprinting device and in vivo applications · Horizon Europe grant · 2023-05-01–2026-04-30
EC contribution
Total cost
Beneficiaries
About the data
Source: CORDIS (official EU open data), Horizon Europe. Framework HORIZON · call HORIZON-EIC-2022-ACCELERATOR-01 · scheme HORIZON-EIC-ACC-BF · topic HORIZON-EIC-2022-ACCELERATORCHALLENGES-01. CORDIS record →
Objective
PhosPrint's D-LIB platform technology is based on a compact and automated laser bioprinter and protocols for high-speed and high-precision in-vivo printing of tissues with autologous human body characteristics. The bioprinter relies on the Laser Induced Forward Transfer (LIFT) technique to accomplish highly accurate and cost-effective printing of tissues. The bioprinter system is associated with protocols for cell isolation from autologous biopsies, cell expansion in-vitro, and cell printing in-vivo. This is a truly new approach that allows for real-time tissue engineering/repair in complex medical conditions. D-LIB capabilities will enable the introduction of a laser bioprinting technology in surgery operations, starting with enterocystoplasty/augmentation in cystectomy bladder cancer patients as the selected go-to-market application.
Beneficiaries (1)
| Organisation | Country | Role | EC contribution | SME |
|---|---|---|---|---|
| PHOSPRINT ANONYMI ETAIREIA | EL | coordinator | €2,000,560 | Yes |
Get the DFM funding briefing — free
New EU defence calls, tenders and awards in your inbox.
Defence Finance Monitor is an analytical and informational product. Grant data is official CORDIS; payment and subscription happen on DFM Analysis.